Company: HCTI
Filing Date: 2025-05-09
Form Type: S-1/A
Source: 0001213900-25-041190
Chunk: 14

Company: Healthcare Triangle, Inc.
Filing Date: 2025-05-09
Form: S-1/A
Chunk 14
---
 holder will receive 3 shares of Common Stock for each Series B Warrant
they exercise, without any cash payment to us. If a “zero exercise price” option is utilized, such exercise will result in
substantial dilution to stockholders. As a result of this feature, we do not expect to receive any cash proceeds from the exercise of
the Series B Warrants in these circumstances because it is highly unlikely that a Series B Warrant holder will elect to pay an exercise
price in cash to receive one share of Common Stock at a time when they could elect the zero exercise price option to receive more shares
of Common Stock than they would receive if they did pay an exercise price. If each holder of the Series B Warrants elects the zero exercise
price option, the number of shares of Common Stock could increase to up to 30 shares of Common Stock underlying each Series B Warrant
if the exercise price decreases to and equals the Floor Price at the time of such election. As such, holders of the Series B Warrants
may elect to be issued up to 1,085,714,550 shares of Common Stock upon the exercise of the Series B Warrants assuming the $0.084 Floor
Price. If holders of the Series B Warrants elect the zero exercise price option, on this basis, such exercise will result in substantial
dilution to stockholders.

<div align='center'>5</div>

We may not be able to maintain the listing of our Common Stock on Nasdaq, which could adversely affect our liquidity and the trading volume and market price of our Common Stock and decrease or eliminate your investment.

Nasdaq requires listing issuers to comply
with certain standards to remain listed on its exchange. If, for any reason, Nasdaq should delist our securities from trading on its
exchange and we are unable to obtain listing on another reputable national securities exchange, a reduction in some or all of the following
may occur, each of which could materially adversely affect our stockholders.

On February 26, 2025, we received a letter
from Nasdaq notifying us that we were no longer in compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq
under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Although Nasdaq has granted us 180 calendar days, or until August
25, 2025 (the “Compliance Period”) to regain compliance with the Bid Price Rule, in connection with